Stocktoria
Coloplast A/S COLO-B.CO
DK · Nasdaq Copenhagen · XCSE · stock · Healthcare · website
Coloplast A/S financials (annual, from 10-K)
Bars are annual figures from 2021 to 2024; red bars are negative (a loss or cash outflow).
| Metric | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | kr 27.0B | kr 24.5B | kr 22.6B | kr 19.4B |
| Gross profit | kr 18.3B | kr 16.3B | kr 15.5B | kr 13.3B |
| R&D expense | kr 913.0M | kr 872.0M | kr 866.0M | kr 755.0M |
| SG&A expense | kr 10.1B | kr 8.6B | kr 7.8B | kr 6.2B |
| Operating income | kr 7.3B | kr 6.8B | kr 6.9B | kr 6.4B |
| Interest expense | kr 795.0M | kr 638.0M | kr 172.0M | kr 25.0M |
| Income tax | kr 1.3B | kr 1.2B | kr 1.4B | kr 1.4B |
| Net income | kr 5.1B | kr 4.8B | kr 4.7B | kr 4.8B |
| EPS (diluted) | kr 22.46 | kr 22.20 | kr 22.11 | kr 22.63 |
| Operating cash flow | kr 2.8B | kr 4.2B | kr 5.1B | kr 5.3B |
| Free cash flow | kr 1.4B | kr 3.0B | kr 4.0B | kr 3.3B |
| Cash & equivalents | kr 788.0M | kr 911.0M | kr 414.0M | kr 448.0M |
| Inventory | kr 3.7B | kr 3.5B | kr 3.2B | kr 2.4B |
| Total assets | kr 48.1B | kr 48.2B | kr 37.4B | kr 15.8B |
| Total liabilities | kr 30.1B | kr 30.9B | kr 29.2B | kr 7.7B |
| Shareholders' equity | kr 17.9B | kr 17.3B | kr 8.3B | kr 8.2B |
Growth · year-over-year · Revenue CAGR 11.6%
| Metric | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue growth | +10.3% | +8.5% | +16.2% | — |
| Net income growth | +5.6% | +1.6% | -2.5% | — |
| EPS growth | +1.2% | +0.4% | -2.3% | — |
| Free cash flow growth | -52.4% | -24.7% | +19.3% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Source: company filings via Yahoo Finance · DK · as of 2024-09-30. Figures in DKK; non-US fundamentals are aggregated by Yahoo (shorter history); facts plus Stocktoria's own computed scores — not investment advice.